PMID- 32203091
OWN - NLM
STAT- MEDLINE
DCOM- 20210708
LR  - 20230210
IS  - 1530-0285 (Electronic)
IS  - 0893-3952 (Linking)
VI  - 33
IP  - 8
DP  - 2020 Aug
TI  - A clinicopathological study of 30 breast cancer cases with a HER2/CEP17 ratio of 
      >/=2.0 but an average HER2 copy number of <4.0 signals per cell.
PG  - 1557-1562
LID - 10.1038/s41379-020-0519-y [doi]
AB  - The American Society of Clinical Oncology (ASCO)/College of American Pathologists 
      (CAP) have recently issued updated guidelines on human epidermal growth factor 
      receptor 2 (HER2) testing by fluorescence in situ hybridization (FISH) in 
      invasive breast cancers. Cases with a HER2/chromosome enumeration probe 17 
      (CEP17) ratio of >/=2.0 but an average HER2 copy number of <4.0 signals per cell 
      (ISH group 2) are no longer automatically classified as ISH positive. Herein, 30 
      cases in ISH group 2 were collected. Another 100 patients with a HER2/CEP17 ratio 
      <2.0 and <4.0 HER2 signals per cell (ISH group 5) and 100 patients with a 
      HER2/CEP17 ratio of >/=2.0 and an average HER2 copy number of >/=4.0 signals per cell 
      (ISH group 1) were also recruited for comparison. According to the 2018 ASCO/CAP 
      guidelines, all the cases in ISH group 2 were categorized as HER2 negative. The 
      clinicopathological characteristics of the patients in ISH group 2 were 
      intermediate between ISH group 1 and group 5. Survival analyses revealed that 
      there was no significant disease-free survival (DFS) and overall survival (OS) 
      difference between patients with or without targeted therapy in ISH group 2, as 
      well as between patients with targeted therapy in ISH group 1 and patients in ISH 
      group 2. Patients without targeted therapy in ISH group 2 had a significantly 
      worse OS than patients with targeted therapy in ISH group 1 and patients in ISH 
      group 5. In conclusion, patients in ISH group 2 represent a biologically 
      heterogeneous subset, which are different from those in ISH group 1 and 5. A 
      larger cohort of patients in ISH group 2 should be included for future researches 
      to define the efficacy of HER2-targeted therapy.
FAU - Wang, Xiaoling
AU  - Wang X
AD  - Department of Pathology, the First Affiliated Hospital of Zhejiang University, 
      Hangzhou, Zhejiang, China.
FAU - Teng, Xiaodong
AU  - Teng X
AD  - Department of Pathology, the First Affiliated Hospital of Zhejiang University, 
      Hangzhou, Zhejiang, China.
FAU - Ding, Wei
AU  - Ding W
AD  - Department of Pathology, the First Affiliated Hospital of Zhejiang University, 
      Hangzhou, Zhejiang, China.
FAU - Sun, Ke
AU  - Sun K
AD  - Department of Pathology, the First Affiliated Hospital of Zhejiang University, 
      Hangzhou, Zhejiang, China.
FAU - Wang, Bo
AU  - Wang B
AD  - Department of Pathology, the First Affiliated Hospital of Zhejiang University, 
      Hangzhou, Zhejiang, China. 1506128@zju.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20200316
PL  - United States
TA  - Mod Pathol
JT  - Modern pathology : an official journal of the United States and Canadian Academy 
      of Pathology, Inc
JID - 8806605
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*analysis
MH  - Breast Neoplasms/pathology
MH  - DNA Copy Number Variations
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Receptor, ErbB-2/*analysis
EDAT- 2020/03/24 06:00
MHDA- 2021/07/09 06:00
CRDT- 2020/03/24 06:00
PHST- 2020/01/23 00:00 [received]
PHST- 2020/02/27 00:00 [accepted]
PHST- 2020/02/26 00:00 [revised]
PHST- 2020/03/24 06:00 [pubmed]
PHST- 2021/07/09 06:00 [medline]
PHST- 2020/03/24 06:00 [entrez]
AID - S0893-3952(22)00798-0 [pii]
AID - 10.1038/s41379-020-0519-y [doi]
PST - ppublish
SO  - Mod Pathol. 2020 Aug;33(8):1557-1562. doi: 10.1038/s41379-020-0519-y. Epub 2020 
      Mar 16.